Imvanex (Modified Vaccinia Ankara – Bavarian Nordic Live Virus)

Modified Vaccinia Ankara (MVA), the active ingredient in Imvanex, is a vaccine presented as an injectable solution for subcutaneous use. It is a replication‑deficient live virus that induces immunity and is indicated for the prevention of smallpox and monkeypox in at‑risk populations.

GNH USA supplies Imvanex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imvanex is a live‑virus vaccine used to prevent orthopoxvirus infections.

Smallpox: provides protective immunity against variola virus and reduces disease severity. Monkeypox: lowers the risk of infection and transmission of monkeypox virus. Pre‑exposure prophylaxis for high‑risk individuals: offers immunity before potential exposure to orthopoxviruses. Laboratory personnel handling orthopoxviruses: safeguards staff who may encounter live virus samples.

Common Side Effects: - Injection site pain, redness, or swelling. - Mild fever or chills. - Headache or fatigue. - Muscle aches or joint discomfort. - Transient lymphadenopathy.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis. - Extensive skin rash or Stevens‑Johnson‑like syndrome. - Neurological events such as encephalitis. - Cardiac inflammation including myocarditis. - Thrombocytopenia or bleeding disorders.

Precautions should be observed when using Imvanex. - Immunocompromised patients: avoid use due to risk of uncontrolled viral replication. - Pregnancy: use only if clearly needed, as safety data are limited. - Breastfeeding: consider potential transmission to infant; weigh benefits and risks. - History of severe allergic reaction to vaccinia or vaccine components: contraindicated. - Skin conditions such as eczema or atopic dermatitis: assess risk of disseminated infection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other therapies.

Major Interactions (Avoid): - Concurrent administration of other live viral vaccines: may interfere with immune response. - High‑dose systemic corticosteroids or immunosuppressants: can diminish vaccine efficacy. - Chemotherapy or radiotherapy: increased risk of adverse events.

Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., cidofovir): may reduce viral replication and affect immunogenicity. - Immunomodulatory biologics (e.g., TNF inhibitors): monitor immune response. - Recent receipt of blood products: may transiently affect antibody development.